MYNZ
MYNZ
NASDAQ · Biotechnology

Mainz Biomed Nv

$0.44
-0.03 (-6.22%)
Financial Highlights (FY 2026)
Revenue
13.40M
Net Income
-324,497,536
Gross Margin
64.3%
Profit Margin
-2,421.8%
Rev Growth
+15.5%
D/E Ratio
0.37
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 64.3% 64.3% 39.8% 39.8%
Operating Margin -2,088.1% -1,879.3% -3.7% -3.3%
Profit Margin -2,421.8% -2,300.7% -3.2% -3.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 13.40M 11.60M 1.76M 1.56M
Gross Profit 8.62M 7.46M 701.2K 621.1K
Operating Income -279,771,872 -217,985,182 -65,674 -51,454
Net Income -324,497,536 -252,833,332 -56,960 -48,803
Gross Margin 64.3% 64.3% 39.8% 39.8%
Operating Margin -2,088.1% -1,879.3% -3.7% -3.3%
Profit Margin -2,421.8% -2,300.7% -3.2% -3.1%
Rev Growth +15.5% +15.5% +11.5% -6.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.03M 1.03M 1.22M 1.09M
Total Equity 2.79M 2.79M 4.09M 3.85M
D/E Ratio 0.37 0.37 0.30 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -293,256,752 -241,185,970 -70,729 -65,893
Free Cash Flow -37,098 -32,467